{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:20:27Z","timestamp":1788481227344,"version":"build-2803163510"},"reference-count":39,"publisher":"Zhejiang University Press","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Zhejiang Univ. Sci. B"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1631\/jzus.b2500191","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T07:18:21Z","timestamp":1774250301000},"page":"310-320","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting WTAP sensitizes hepatocellular carcinoma to sorafenib by inhibiting the ERK signaling pathway","\u9776\u5411 WTAP \u901a\u8fc7\u6291\u5236ERK\u4fe1\u53f7\u901a\u8def\u589e\u5f3a\u809d\u7ec6\u80de\u764c\u5bf9\u7d22\u62c9\u975e\u5c3c\u6cbb\u7597\u7684\u654f\u611f\u6027"],"prefix":"10.1631","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4246-4342","authenticated-orcid":false,"given":"Yu","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guomin","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1459-8261","authenticated-orcid":false,"given":"Shusen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0800-1417","authenticated-orcid":false,"given":"Chuanhui","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"635","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"issue":"10","key":"191_CR1","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.3390\/cancers11101618","volume":"11","author":"C Braicu","year":"2019","unstructured":"Braicu C, Buse M, Busuioc C, et al., 2019. A comprehensive review on MAPK: a promising therapeutic target in cancer. Cancers, 11(10):1618. https:\/\/doi.org\/10.3390\/cancers11101618","journal-title":"Cancers"},{"issue":"8","key":"191_CR2","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1172\/JCI127201","volume":"129","author":"YH Cao","year":"2019","unstructured":"Cao YH, 2019. Adipocyte and lipid metabolism in cancer drug resistance. J Clin Invest, 129(8):3006\u20133017. https:\/\/doi.org\/10.1172\/JCI127201","journal-title":"J Clin Invest"},{"issue":"1","key":"191_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2015.06.019","volume":"367","author":"J Chen","year":"2015","unstructured":"Chen J, Jin RN, Zhao J, et al., 2015. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma. Cancer Lett, 367(1): 1\u201311. https:\/\/doi.org\/10.1016\/j.canlet.2015.06.019","journal-title":"Cancer Lett"},{"key":"191_CR4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12943-019-1053-8","volume":"18","author":"YH Chen","year":"2019","unstructured":"Chen YH, Peng CH, Chen JR, et al., 2019. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1. Mol Cancer, 18: 127. https:\/\/doi.org\/10.1186\/s12943-019-1053-8","journal-title":"Mol Cancer"},{"issue":"1","key":"191_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen ZD, et al., 2009. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol, 10(1): 25\u201334. https:\/\/doi.org\/10.1016\/S1470-2045(08)70285-7","journal-title":"Lancet Oncol"},{"issue":"6","key":"191_CR6","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ccell.2018.05.003","volume":"33","author":"D Dhar","year":"2018","unstructured":"Dhar D, Antonucci L, Nakagawa H, et al., 2018. Liver cancer initiation requires p53 inhibition by CD44-enhanced growth factor signaling. Cancer Cell, 33(6):1061\u20131077.e6. https:\/\/doi.org\/10.1016\/j.ccell.2018.05.003","journal-title":"Cancer Cell"},{"issue":"1","key":"191_CR7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.hbpd.2024.08.004","volume":"24","author":"CL Fu","year":"2025","unstructured":"Fu CL, Zhao ZW, Zhang QN, 2025. The crosstalk between cellular survival pressures and N6-methyladenosine modification in hepatocellular carcinoma. Hepatob Pancreat Dis Int, 24(1):67\u201375. https:\/\/doi.org\/10.1016\/j.hbpd.2024.08.004","journal-title":"Hepatob Pancreat Dis Int"},{"issue":"1","key":"191_CR8","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"PR Galle","year":"2018","unstructured":"Galle PR, Forner A, Llovet JM, et al., 2018. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol, 69(1):182\u2013236. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.019","journal-title":"J Hepatol"},{"issue":"3","key":"191_CR9","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1001\/jamaoncol.2021.6987","volume":"8","author":"Global Burden of Disease 2019 Cancer Collaboration","year":"2022","unstructured":"Global Burden of Disease 2019 Cancer Collaboration, 2022. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the global burden of disease study 2019. JAMA Oncol, 8(3):420\u2013444. https:\/\/doi.org\/10.1001\/jamaoncol.2021.6987","journal-title":"JAMA Oncol"},{"key":"191_CR10","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","volume":"5","author":"B Hu","year":"2020","unstructured":"Hu B, Zhong LP, Weng YH, et al., 2020. Therapeutic siRNA: state of the art. Sig Transduct Target Ther, 5:101. https:\/\/doi.org\/10.1038\/s41392-020-0207-x","journal-title":"Sig Transduct Target Ther"},{"issue":"7478","key":"191_CR11","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/nature12688","volume":"504","author":"CM Johannessen","year":"2013","unstructured":"Johannessen CM, Johnson LA, Piccioni F, et al., 2013. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature, 504(7478):138\u2013142. https:\/\/doi.org\/10.1038\/nature12688","journal-title":"Nature"},{"issue":"2","key":"191_CR12","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s11523-017-0484-7","volume":"12","author":"GM Keating","year":"2017","unstructured":"Keating GM, 2017. Sorafenib: a review in hepatocellular carcinoma. Targ Oncol, 12(2):243\u2013253. https:\/\/doi.org\/10.1007\/s11523-017-0484-7","journal-title":"Targ Oncol"},{"key":"191_CR13","doi-asserted-by":"publisher","first-page":"26075","DOI":"10.1038\/s41598-024-77941-2","volume":"14","author":"TJ Li","year":"2024","unstructured":"Li TJ, Huang YQ, Cui SE, et al., 2024. RNA methylation patterns of tumor microenvironment cells regulate prognosis and immunotherapeutic responsiveness in patients with triple-negative breast cancer. Sci Rep, 14:26075. https:\/\/doi.org\/10.1038\/s41598-024-77941-2","journal-title":"Sci Rep"},{"issue":"27","key":"191_CR14","doi-asserted-by":"publisher","first-page":"2302025","DOI":"10.1002\/advs.202302025","volume":"10","author":"YN Liao","year":"2023","unstructured":"Liao YN, Liu Y, Yu CF, et al., 2023. HSP90\u03b2 impedes STUB1-induced ubiquitination of YTHDF2 to drive sorafenib resistance in hepatocellular carcinoma. Adv Sci, 10(27): 2302025. https:\/\/doi.org\/10.1002\/advs.202302025","journal-title":"Adv Sci"},{"issue":"2","key":"191_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nchembio.1432","volume":"10","author":"JZ Liu","year":"2014","unstructured":"Liu JZ, Yue YN, Han DL, et al., 2014. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol, 10(2):93\u201395. https:\/\/doi.org\/10.1038\/nchembio.1432","journal-title":"Nat Chem Biol"},{"issue":"7674","key":"191_CR16","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nature24040","volume":"550","author":"HZ Lu","year":"2017","unstructured":"Lu HZ, Liu SJ, Zhang G, et al., 2017. PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature, 550(7674):133\u2013136. https:\/\/doi.org\/10.1038\/nature24040","journal-title":"Nature"},{"issue":"6","key":"191_CR17","doi-asserted-by":"publisher","first-page":"bbab260","DOI":"10.1093\/bib\/bbab260","volume":"22","author":"D Maeser","year":"2021","unstructured":"Maeser D, Gruener RF, Huang RS, et al., 2021. oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Brief Bioinform, 22(6):bbab260. https:\/\/doi.org\/10.1093\/bib\/bbab260","journal-title":"Brief Bioinform"},{"issue":"4","key":"191_CR18","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.ccr.2014.04.002","volume":"25","author":"JU Marquardt","year":"2014","unstructured":"Marquardt JU, Thorgeirsson SS, 2014. SnapShot: hepatocellular carcinoma. Cancer Cell, 25(4):550\u2013550.e1. https:\/\/doi.org\/10.1016\/j.ccr.2014.04.002","journal-title":"Cancer Cell"},{"issue":"5","key":"191_CR19","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1016\/j.nano.2017.03.006","volume":"13","author":"M Paolini","year":"2017","unstructured":"Paolini M, Poul L, Darmon A, et al., 2017. A new opportunity for nanomedicines: micellar cytochrome P450 inhibitors to improve drug efficacy in a cancer therapy model. Nanomed Nanotechnol Biol Med, 13(5):1715\u20131723. https:\/\/doi.org\/10.1016\/j.nano.2017.03.006","journal-title":"Nanomed Nanotechnol Biol Med"},{"issue":"6","key":"191_CR20","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1021\/acs.jmedchem.5b01948","volume":"59","author":"TP Prakash","year":"2016","unstructured":"Prakash TP, Yu JH, Migawa MT, et al., 2016. Comprehensive structure-activity relationship of triantennary N-acetylgalactosamine conjugated antisense oligonucleotides for targeted delivery to hepatocytes. J Med Chem, 59(6): 2718\u20132733. https:\/\/doi.org\/10.1021\/acs.jmedchem.5b01948","journal-title":"J Med Chem"},{"issue":"1","key":"191_CR21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1517\/14728222.2011.645805","volume":"16","author":"L Santarpia","year":"2012","unstructured":"Santarpia L, Lippman SM, El-Naggar AK, 2012. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targ, 16(1): 103\u2013119. https:\/\/doi.org\/10.1517\/14728222.2011.645805","journal-title":"Expert Opin Ther Targ"},{"key":"191_CR22","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12935-024-03307-3","volume":"24","author":"YX Shi","year":"2024","unstructured":"Shi YX, Li K, Yuan YC, et al., 2024. Comprehensive analysis of m6A modification in immune infiltration, metabolism and drug resistance in hepatocellular carcinoma. Cancer Cell Int, 24:138. https:\/\/doi.org\/10.1186\/s12935-024-03307-3","journal-title":"Cancer Cell Int"},{"issue":"1","key":"191_CR23","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A, 2024. Cancer statistics, 2024. CA Cancer J Clin, 74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"191_CR24","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.3390\/cells10102509","volume":"10","author":"R Sugiura","year":"2021","unstructured":"Sugiura R, Satoh R, Takasaki T, 2021. ERK: a double-edged sword in cancer. ERK-dependent apoptosis as a potential therapeutic strategy for cancer. Cells, 10(10):2509. https:\/\/doi.org\/10.3390\/cells10102509","journal-title":"Cells"},{"key":"191_CR25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41392-020-0187-x","volume":"5","author":"WW Tang","year":"2020","unstructured":"Tang WW, Chen ZY, Zhang WL, et al., 2020. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Sig Transduct Target Ther, 5:87. https:\/\/doi.org\/10.1038\/s41392-020-0187-x","journal-title":"Sig Transduct Target Ther"},{"issue":"10360","key":"191_CR26","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","volume":"400","author":"A Vogel","year":"2022","unstructured":"Vogel A, Meyer T, Sapisochin G, et al., 2022. Hepatocellular carcinoma. Lancet, 400(10360):1345\u20131362. https:\/\/doi.org\/10.1016\/S0140-6736(22)01200-4","journal-title":"Lancet"},{"issue":"12","key":"191_CR27","doi-asserted-by":"publisher","first-page":"5550","DOI":"10.7150\/thno.42633","volume":"10","author":"Q Wang","year":"2020","unstructured":"Wang Q, Sun MC, Li D, et al., 2020. Cytochrome P450 enzymemediated auto-enhanced photodynamic cancer therapy of co-nanoassembly between clopidogrel and photosensitizer. Theranostics, 10(12):5550\u20135564. https:\/\/doi.org\/10.7150\/thno.42633","journal-title":"Theranostics"},{"issue":"51","key":"191_CR28","doi-asserted-by":"publisher","first-page":"eabg3750","DOI":"10.1126\/sciadv.abg3750","volume":"7","author":"R Wu","year":"2021","unstructured":"Wu R, Guo WB, Qiu XY, et al., 2021. Comprehensive analysis of spatial architecture in primary liver cancer. Sci Adv, 7(51): eabg3750. https:\/\/doi.org\/10.1126\/sciadv.abg3750","journal-title":"Sci Adv"},{"key":"191_CR29","doi-asserted-by":"publisher","first-page":"102610","DOI":"10.1016\/j.ebiom.2019.102610","volume":"51","author":"SJ Xia","year":"2020","unstructured":"Xia SJ, Pan Y, Liang YL, et al., 2020. The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma. EBioMedicine, 51: 102610. https:\/\/doi.org\/10.1016\/j.ebiom.2019.102610","journal-title":"EBioMedicine"},{"key":"191_CR30","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41392-020-00375-5","volume":"5","author":"JJ Xu","year":"2020","unstructured":"Xu JJ, Ji L, Liang YL, et al., 2020a. CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1. Sig Transduct Target Ther, 5:298. https:\/\/doi.org\/10.1038\/s41392-020-00375-5","journal-title":"Sig Transduct Target Ther"},{"key":"191_CR31","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12943-020-01281-8","volume":"19","author":"JJ Xu","year":"2020","unstructured":"Xu JJ, Wan Z, Tang MY, et al., 2020b. N6-methyladenosine-modified circRNA-SORE sustains sorafenib resistance in hepatocellular carcinoma by regulating \u03b2-catenin signaling. Mol Cancer, 19:163. https:\/\/doi.org\/10.1186\/s12943-020-01281-8","journal-title":"Mol Cancer"},{"key":"191_CR32","doi-asserted-by":"publisher","first-page":"1442765","DOI":"10.3389\/fphar.2024.1442765","volume":"15","author":"DD Zhang","year":"2024","unstructured":"Zhang DD, Cai Y, Sun YX, et al., 2024. A real-world pharmacovigilance study of Sorafenib based on the FDA Adverse Event Reporting System. Front Pharmacol, 15:1442765. https:\/\/doi.org\/10.3389\/fphar.2024.1442765","journal-title":"Front Pharmacol"},{"issue":"6","key":"191_CR33","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1158\/0008-5472.CAN-23-1916","volume":"84","author":"XY Zhang","year":"2024","unstructured":"Zhang XY, Su TH, Wu YF, et al., 2024. N6-methyladenosine reader YTHDF1 promotes sternness and therapeutic resistance in hepatocellular carcinoma by enhancing NOTCH1 expression. Cancer Res, 84(6):827\u2013840. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-1916","journal-title":"Cancer Res"},{"key":"191_CR34","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1741-7015-7-41","volume":"7","author":"Z Zhang","year":"2009","unstructured":"Zhang Z, Zhou XY, Shen HJ, et al., 2009. Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. BMC Med, 7:41. https:\/\/doi.org\/10.1186\/1741-7015-7-41","journal-title":"BMC Med"},{"issue":"23","key":"191_CR35","doi-asserted-by":"publisher","first-page":"12808","DOI":"10.3390\/ijms222312808","volume":"22","author":"MZ Zhao","year":"2021","unstructured":"Zhao MZ, Ma JS, Li M, et al., 2021. Cytochrome P450 enzymes and drug metabolism in humans. Int J Mol Sci, 22(23): 12808. https:\/\/doi.org\/10.3390\/ijms222312808","journal-title":"Int J Mol Sci"},{"issue":"1","key":"191_CR36","doi-asserted-by":"publisher","first-page":"e70117","DOI":"10.1002\/jbt.70117","volume":"39","author":"CF Zhou","year":"2025","unstructured":"Zhou CF, Wang M, Du XM, et al., 2025. WTAP\/IGF2BP3 mediated m6A modification of SOD2 mRNA aggravates the tumourigenesis of colorectal cancer. J Biochem Mol Toxicol, 39(1):e70117. https:\/\/doi.org\/10.1002\/jbt.70117","journal-title":"J Biochem Mol Toxicol"},{"key":"191_CR37","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41392-020-00299-0","volume":"5","author":"TF Zhou","year":"2020","unstructured":"Zhou TF, Li SC, Xiang DM, et al., 2020. m6A RNA methylation-mediated HNF3\u03b3 reduction renders hepatocellular carcinoma dedifferentiation and sorafenib resistance. Sig Transduct Target Ther, 5:296. https:\/\/doi.org\/10.1038\/s41392-020-00299-0","journal-title":"Sig Transduct Target Ther"},{"issue":"23","key":"191_CR38","doi-asserted-by":"publisher","first-page":"e70207","DOI":"10.1111\/jcmm.70207","volume":"28","author":"XX Zhu","year":"2024","unstructured":"Zhu XX, Chen XY, Zhao LT, et al., 2024. WTAP-mediated m6A modification of circSMOC1 accelerates the tumorigenesis of non-small cell lung cancer by regulating miR-612\/CCL28 axis. J Cell Mol Med, 28(23):e70207. https:\/\/doi.org\/10.1111\/jcmm.70207","journal-title":"J Cell Mol Med"},{"issue":"5","key":"191_CR39","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/aps.2017.5","volume":"38","author":"YJ Zhu","year":"2017","unstructured":"Zhu YJ, Zheng B, Wang HY, et al., 2017. New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacol Sin, 38(5):614\u2013622. https:\/\/doi.org\/10.1038\/aps.2017.5","journal-title":"Acta Pharmacol Sin"}],"container-title":["Journal of Zhejiang University-SCIENCE B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1631\/jzus.B2500191.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1631\/jzus.B2500191","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1631\/jzus.B2500191.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T20:02:05Z","timestamp":1774296125000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1631\/jzus.B2500191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["191"],"URL":"https:\/\/doi.org\/10.1631\/jzus.b2500191","relation":{},"ISSN":["1673-1581","1862-1783"],"issn-type":[{"value":"1673-1581","type":"print"},{"value":"1862-1783","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"16 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yu WU, Guomin JU, Xueyu ZHOU, Jian WU, Shusen ZHENG, and Chuanhui PENG declare that they have no conflicts of interest.All animal procedures strictly adhered to ethical standards and were formally authorized by the Institutional Animal Ethics Committee of The First Affiliated Hospital, Zhejiang University School of Medicine (Ethics Approval No. 2025069).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics guidelines"}},{"value":"During the preparation of this work, the authors used DeepSeek in order to improve language and readability and check for grammatical errors. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration on the use of generative AI tools"}}]}}